Eli Lilly and Company (LLY) – Attractive Stock for Investors

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Eli Lilly and Company (LLY) (Q1FY23)

Highlights

Eli Lilly and Company is experiencing revenue growth due to increased demand for drugs such as Trulicity, Taltz, and others. In 2023, several factors are contributing to the positive momentum and driving Lilly’s stock higher. These factors include the strong performance of existing drugs, the anticipation of promising new drug launches, and investor confidence in the company’s future prospects.

The stock price showed an upward trend in past 3-months period. It gave 32.85% returns during the period. The stock price increased 36.32% in past 1-year. The stock has a 52-week high of $454.95 and its 52-week low is $283.11.

In the past 3 years, the stock has given returns of 188.8%. LLY has a 50-day moving Avg. and 200-day moving Avg. of $389.25 and $351.50, respectively

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– PE Band Comparison
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 37

To download the previous quarter’s equity report CLICK HERE

Follow our LinkedIn page for more updates